RECRUITING

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Description

This study investigates whether intravenous (IV) iron \[Feraheme (ferumoxytol) injection)\] is a better treatment than oral iron pills (ferrous sulfate) for correcting anemia in women who have heavy menstrual bleeding and anemia. Investigators will study whether women's blood counts respond better, respond more quickly, and if women prefer the IV treatment or the oral treatment. Women who have heavy menstrual bleeding and anemia will be randomly assigned to receive treatment with either oral iron pills or IV iron infusions. Investigators will then check whether and how quickly the anemia improves, and survey participants on how satisfied they were with the treatment.

Study Overview

Study Details

Study overview

This study investigates whether intravenous (IV) iron \[Feraheme (ferumoxytol) injection)\] is a better treatment than oral iron pills (ferrous sulfate) for correcting anemia in women who have heavy menstrual bleeding and anemia. Investigators will study whether women's blood counts respond better, respond more quickly, and if women prefer the IV treatment or the oral treatment. Women who have heavy menstrual bleeding and anemia will be randomly assigned to receive treatment with either oral iron pills or IV iron infusions. Investigators will then check whether and how quickly the anemia improves, and survey participants on how satisfied they were with the treatment.

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Condition
Anemia, Iron Deficiency
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Thomas Jefferson University, Philadelphia, Pennsylvania, United States, 19107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women aged 18-50.
  • * Heavy menstrual bleeding, defined as self-report of bothersome periods with subjectively heavy flow or frequency greater than 7 bleeding days per month.
  • * Anemia with hgb \<11.5 g/dL
  • * Suspected/confirmed malignancy
  • * Severe anemia currently requiring transfusion or emergent operative intervention
  • * Allergy or contraindication to either study drug
  • * Known iron overload
  • * Known sickle cell disease

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Thomas Jefferson University,

Study Record Dates

2025-01